Kartik Sehgal

Employment

• Dana-Farber Cancer Institute Medical Oncologist
  2020 - Present
• Dana Farber Cancer Institute Research Fellow
  2018 - 2020
• Beth Israel Deaconess Medical Center Clinical Fellow
  2017 - 2020
• Yale University School of Medicine Resident
  2014 - 2017
• Yale University Postdoctoral associate, Dhodapkar Lab
  2011 - 2014

Education

• All India Institute of Medical Sciences MD

Projects & Funding

Projects & funding information is unavailable.

Publications (93)

• Figure S1 from A Prospective Trial of Biomarker-Guided Surveillance for HPV-Positive Oropharynx Cancer Using Plasma Tumor Tissue–Modified Viral HPV DNA
  2026 DOI: 10.1158/1078-0432.32711303
  +Save
• Data from A Prospective Trial of Biomarker-Guided Surveillance for HPV-Positive Oropharynx Cancer Using Plasma Tumor Tissue–Modified Viral HPV DNA
  2026 DOI: 10.1158/1078-0432.c.7797415
  +Save
• Decoding tumor microenvironment and resistance following immune checkpoint inhibition therapy in anaplastic thyroid carcinoma
  CANCER IMMUNOLOGY RESEARCH 2026 DOI: 10.1158/2326-6074.IO2026-B057
  +Save
• Preliminary Safety and Efficacy of Tarlatamab in Medullary Thyroid Carcinoma
  JCO Oncology Advances 2026 DOI: 10.1200/OA-25-00116
  +Save
• Elraglusib, a Glycogen Synthase Kinase 3β Inhibitor, plus Chemotherapy with or without Immunotherapy in Patients with Recurrent, Metastatic Salivary Gland Carcinoma
  Clinical Cancer Research 2026 DOI: 10.1158/1078-0432.CCR-25-2731
  +Save
• Tarlatamab: Precision Delta-Like Ligand 3 Bispecific T-Cell Engager for Malignancies Beyond De Novo Small Cell Lung Cancer?
  JCO Precision Oncology 2026 DOI: 10.1200/PO-26-00008
  +Save
• PTPN2 inhibition unleashes response to STING agonism in head and neck squamous cell cancer
  Nature Communications 2026 DOI: 10.1038/s41467-026-72372-1
  +Save
• First-in-Human, Phase I Study of Sigvotatug Vedotin, an Integrin Beta-6–Directed Antibody-Drug Conjugate: Results From Dose Expansion in Advanced Non–Small Cell Lung Cancer
  Journal of Clinical Oncology 2026 DOI: 10.1200/JCO-25-02016
  +Save
• Table S6 from A Prospective Trial of Biomarker-Guided Surveillance for HPV-Positive Oropharynx Cancer Using Plasma Tumor Tissue–Modified Viral HPV DNA
  2026 DOI: 10.1158/1078-0432.32711276
  +Save
• Table S5 from A Prospective Trial of Biomarker-Guided Surveillance for HPV-Positive Oropharynx Cancer Using Plasma Tumor Tissue–Modified Viral HPV DNA
  2026 DOI: 10.1158/1078-0432.32711279
  +Save